We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock

Delisted

SEEL was delisted on the 15th of October, 2024.

32 hedge funds and large institutions have $2.58M invested in Seelos Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,462% more call options, than puts

Call options by funds: $538K | Put options by funds: $21K

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

52% less funds holding

Funds holding: 6732 (-35)

63% less capital invested

Capital invested by funds: $7M → $2.58M (-$4.43M)

81% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 43

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
32
Holders Change
-35
Holders Change %
-52.24%
% of All Funds
0.47%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
8
Increased
11
Reduced
7
Closed
43
Calls
$538K
Puts
$21K
Net Calls
+$517K
Net Calls Change
+$357K

SEEL Hedge Fund Activity: Q4 2023 in Review

32 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2023, worth a combined $2.58M — down 63% from $7M a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of SEEL and 8 opened new positions — a net loss of 35 holders — while 7 trimmed existing stakes and 11 added.

The largest buyer was Mirae Asset Global Investments, adding an estimated $1.05M. The largest seller was Sabby Management, exiting entirely with an estimated $2.17M sold.

  • 32 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2023, down from 67 in Q3 2023.
  • Funds reported $2.58M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2023, down 63% quarter-over-quarter.
  • 8 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2023 and 43 closed out, a net change of -35 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2023 was Mirae Asset Global Investments, an estimated $1.05M added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2023 was Sabby Management, an estimated $2.17M sold.

Based on aggregated 13F filings for Q4 2023.